Loading...

Intellectia LogoIntellectia
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. MLAB
MLAB logo

MLAB Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • AI Stock Picker
  • Swing Trading
  • SwingMax Portfolio
  • QuantAI Alpha Pick
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • Financial AI Agent
  • AI Screener
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
91.480
Open
89.700
VWAP
88.69
Vol
137.21K
Mkt Cap
483.92M
Low
87.000
Amount
12.17M
EV/EBITDA(TTM)
15.39
Total Shares
5.52M
EV
650.02M
EV/OCF(TTM)
15.65
P/S(TTM)
2.07
Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.
Show More

Events Timeline

(ET)
2026-02-03
08:10:00
Mesa Reports Q3 Revenue of $65.126M, Beating Consensus
select
2025-11-06 (ET)
2025-11-06
16:44:20
Mesa Labs announces Q2 earnings per share of 45 cents, down from 63 cents a year ago.
select
2025-09-22 (ET)
2025-09-22
04:55:00
S&P Dow Jones Indices Reveals Quarterly Rebalancing Update
select
2025-09-05 (ET)
2025-09-05
17:29:12
S&P Dow Jones Indices Reveals Quarterly Rebalancing Update
select
2025-08-05 (ET)
2025-08-05
08:15:45
Mesa Labs reports Q1 EPS 85c vs 62c last year
select

News

seekingalpha
9.5
02-03seekingalpha
Mesa Laboratories Q4 Earnings Exceed Expectations
  • Earnings Highlights: Mesa Laboratories reported a Q4 GAAP EPS of $0.65, beating expectations by $0.37, indicating a significant enhancement in profitability and reflecting the company's strengthened competitive position in the market.
  • Revenue Growth: The company achieved Q4 revenue of $65.13 million, a 3.6% year-over-year increase, surpassing market expectations by $1.9 million, demonstrating sustained demand and steady market share growth in the medical device sector.
  • Core Business Performance: On a non-GAAP basis, core organic revenue growth was 1.2%, while adjusted operating income (AOI) increased by 17.6% to $17.072 million, further solidifying the company's profitability within the industry.
  • Excluding Unusual Items: Excluding CG China revenues, the non-GAAP organic revenue growth rate was 5.7%, showcasing Mesa Laboratories' robust performance in global markets, particularly in the diagnostics sector's ongoing expansion.
Globenewswire
8.0
01-07Globenewswire
Mesa Laboratories Declares $0.16 Quarterly Dividend Per Share
  • Quarterly Dividend Announcement: Mesa Laboratories has declared a quarterly dividend of $0.16 per share of common stock, payable on March 16, 2026, which aims to reward shareholders and enhance investor confidence.
  • Shareholder Record Date: The dividend will be distributed to shareholders of record at the close of business on February 28, 2026, ensuring eligible shareholders receive their returns promptly, thereby strengthening the company's relationship with investors.
  • Company Background: Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, dedicated to improving product integrity and safety.
  • Forward-Looking Statements: The company cautions investors about the risks and uncertainties associated with forward-looking statements, emphasizing that actual results may differ significantly from expectations, ensuring transparency and compliance.
Globenewswire
1.0
2025-12-19Globenewswire
Mesa Labs CEO to Present at J.P. Morgan Healthcare Conference on January 14, 2026
  • Conference Participation: Mesa Laboratories' CEO Gary Owens and CFO John Sakys will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, showcasing the company's leadership in life science tools and critical quality control solutions.
  • Live Webcast: The formal presentation is scheduled for 4:30 p.m. Pacific Time, and will be accessible via a live webcast, enhancing investor transparency and engagement with the company.
  • Investor Relations: An archived replay of the webcast will be available on Mesa Labs' Investor Relations website after the presentation, ensuring that investors who cannot attend live can still access key information, thereby improving communication efficiency with stakeholders.
  • Company Background: Mesa Laboratories is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries, committed to enhancing product integrity and patient safety, further solidifying its market position.
Newsfilter
1.0
2025-12-19Newsfilter
Mesa Laboratories to Present at 44th Annual J.P. Morgan Healthcare Conference
  • Conference Participation: Mesa Laboratories' CEO Gary Owens and CFO John Sakys will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, showcasing the company's leadership in life science tools and critical quality control solutions.
  • Schedule Details: The formal presentation is set for 4:30 PM Pacific Time, which is expected to attract attention from investors and industry experts, further enhancing the company's visibility in the healthcare sector.
  • Live Webcast: The presentation will be accessible via a live webcast on Mesa Laboratories' Investor Relations website, allowing global investors to receive real-time updates, thereby increasing transparency and investor confidence.
  • Post-Presentation Replay: An archived replay of the webcast will be available through the same link after the presentation, ensuring that investors who cannot attend live can still access key information, promoting ongoing engagement between the company and its investors.
Globenewswire
9.5
2025-12-03Globenewswire
Mesa Laboratories to Release Q3 FY2026 Financial Results on February 3, 2026
  • Earnings Release Schedule: Mesa Laboratories is set to announce its Q3 FY2026 financial results on February 3, 2026, at 8:00 A.M. ET, which will provide investors with critical performance data to assess the company's financial health.
  • Industry Leadership: As a global leader in the design and manufacture of life science tools and critical quality control solutions, Mesa serves the pharmaceutical, healthcare, and medical device industries, aiming to ensure product integrity and enhance patient and worker safety.
  • Customer Value Enhancement: Mesa's products and services not only help clients improve product quality but also focus on enhancing the quality of life worldwide, reflecting the company's significance and impact within the industry.
  • Management Contact Information: CEO Gary Owens and CFO John Sakys are available for contact, further enhancing communication with investors to ensure transparency and trust.
Newsfilter
9.5
2025-12-03Newsfilter
Mesa Laboratories Schedules Q3 FY2026 Financial Results Release
  • Earnings Release Schedule: Mesa Laboratories plans to release its Q3 FY2026 financial results on February 3, 2026, at 8:00 A.M. ET, demonstrating the company's commitment to transparency and investor communication.
  • Industry Leadership: As a global leader in life science tools and critical quality control solutions, Mesa provides essential products in the pharmaceutical, healthcare, and medical device sectors, ensuring product integrity and enhancing patient and worker safety.
  • Customer Service Commitment: Mesa is dedicated to improving quality of life worldwide through its products and services, reflecting the company's strategic goal of meeting customer needs and raising industry standards.
  • Executive Contact Information: CEO Gary Owens and CFO John Sakys can be reached at 303-987-8000, further enhancing communication channels with investors and stakeholders.
Wall Street analysts forecast MLAB stock price to rise
2 Analyst Rating
Wall Street analysts forecast MLAB stock price to rise
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
83.00
Averages
99.00
High
115.00
Current: 0.000
sliders
Low
83.00
Averages
99.00
High
115.00
Wells Fargo
Equal Weight
maintain
$83 -> $94
AI Analysis
2026-02-04
Reason
Wells Fargo
Price Target
$83 -> $94
AI Analysis
2026-02-04
maintain
Equal Weight
Reason
Wells Fargo raised the firm's price target on Mesa Labs to $94 from $83 and keeps an Equal Weight rating on the shares. The firm notes the company posted a solid beat on Q3 revenue and adjusted EBITDA, with strong margin expansion despite foreign-exchange headwinds. With numbers moving up, leverage down and management taking more shareholder-friendly steps, there's more room for valuation to re-rate, in Wells' view.
Wells Fargo
Equal Weight
maintain
$75 -> $83
2025-12-15
Reason
Wells Fargo
Price Target
$75 -> $83
2025-12-15
maintain
Equal Weight
Reason
Wells Fargo raised the firm's price target on Mesa Labs to $83 from $75 and keeps an Equal Weight rating on the shares. With U.S. policy uncertainty lifting on Pharma and forward growth expectations already well-anchored with room for upside, the firm likes the setup for Tools.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MLAB
Unlock Now

Valuation Metrics

The current forward P/E ratio for Mesa Laboratories Inc (MLAB.O) is 62.30, compared to its 5-year average forward P/E of 31.41. For a more detailed relative valuation and DCF analysis to assess Mesa Laboratories Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
31.41
Current PE
62.30
Overvalued PE
47.75
Undervalued PE
15.06

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
18.76
Current EV/EBITDA
9.51
Overvalued EV/EBITDA
25.34
Undervalued EV/EBITDA
12.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
4.04
Current PS
1.73
Overvalued PS
6.18
Undervalued PS
1.90

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

under a half a billion I meant
Intellectia · 427 candidates
Market Cap: <= 500.00MPrice Change Pct: $-5.00 - $5.00Moving Average Relationship: PriceCrossAboveMA5, PriceCrossAboveMA20
Ticker
Name
Market Cap$
top bottom
TCPC logo
TCPC
BlackRock TCP Capital Corp
498.02M
EBF logo
EBF
Ennis Inc
494.48M
RSVR logo
RSVR
Reservoir Media Inc
492.57M
PRTH logo
PRTH
Priority Technology Holdings Inc
490.41M
FBIZ logo
FBIZ
First Business Financial Services Inc
489.38M
MCS logo
MCS
Marcus Corp
488.66M

Whales Holding MLAB

R
Ranger Investment Management, L.P.
Holding
MLAB
-3.87%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Mesa Laboratories Inc (MLAB) stock price today?

The current price of MLAB is 87.59 USD — it has decreased -5.64

What is Mesa Laboratories Inc (MLAB)'s business?

Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.

What is the price predicton of MLAB Stock?

Wall Street analysts forecast MLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLAB is99.00 USD with a low forecast of 83.00 USD and a high forecast of 115.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Mesa Laboratories Inc (MLAB)'s revenue for the last quarter?

Mesa Laboratories Inc revenue for the last quarter amounts to 65.13M USD, increased 3.64

What is Mesa Laboratories Inc (MLAB)'s earnings per share (EPS) for the last quarter?

Mesa Laboratories Inc. EPS for the last quarter amounts to 0.65 USD, decreased -309.68

How many employees does Mesa Laboratories Inc (MLAB). have?

Mesa Laboratories Inc (MLAB) has 730 emplpoyees as of March 05 2026.

What is Mesa Laboratories Inc (MLAB) market cap?

Today MLAB has the market capitalization of 483.92M USD.